title: Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.
abstract: BACKGROUND
  Women with polycystic ovary syndrome (PCOS) have increased 17-hydroxyprogesterone (17-OHP) responses to gonadotropin stimulation although individual variability is substantial, as reflected by exaggerated as well as normal responses. The relationship between 17-OHP responses to gonadotropin stimulation and markers of ovarian function has not been assessed.
  
  
  OBJECTIVE
  To determine whether 17-OHP responses are associated with antral follicle count (AFC), anti-Mullerian hormone (AMH), or inhibin B (Inh B) levels in PCOS and normal women.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Research center at an academic medical center.
  
  
  METHODS
  Women with PCOS (n = 18) and normal controls (n = 18).
  
  
  METHODS
  Blood samples were obtained before and 24 hours after administration of 25 μg recombinant-human chorionic gonadotropin. Ovarian imaging was conducted with three-dimensional pelvic ultrasound.
  
  
  METHODS
  Basal and stimulated levels of 17-OHP, androgens, estrogen, AMH, Inh B, and AFC.
  
  
  RESULTS
  In women with PCOS, 17-OHP responses were heterogeneous and inversely correlated with AMH and Inh B levels, but not AFC. In a subgroup of PCOS women with exaggerated 17-OHP responses, AMH levels were equivalent to that of normal women. In PCOS women with normal 17-OHP responses, AMH levels were markedly elevated.
  
  
  CONCLUSIONS
  Based on heterogeneous 17-OHP responses to human chorionic gonadotropin in women with PCOS, AMH levels are inversely linked to ovarian androgen production while positively correlated with AFC. These findings suggest that in PCOS, AMH production may reflect redistribution of the follicle population or regulation by intraovarian mechanisms.
authors.affiliation: Department of Reproductive Medicine, University of California, San Diego, La Jolla, California 92093.
authors.forename: Kevin H
authors.initials: KH
authors.lastname: Maas
authors.forename: Sandy S
authors.initials: SS
authors.lastname: Chuan
authors.forename: Heidi
authors.initials: H
authors.lastname: Cook-Andersen
authors.forename: H Irene
authors.initials: HI
authors.lastname: Su
authors.forename: A
authors.initials: A
authors.lastname: Duleba
authors.forename: R Jeffrey
authors.initials: RJ
authors.lastname: Chang
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood*; D000328:Adult; D000728:Androgens / Q000097:blood; D054304:Anti-Mullerian Hormone / Q000097:blood; D015415:Biomarkers / Q000097:blood; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007265:Inhibins / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D006080:Ovarian Follicle / Q000000981:diagnostic imaging*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000000981:diagnostic imaging; D011446:Prospective Studies; D014463:Ultrasonography
chemical_list: D000728:Androgens; D015415:Biomarkers; D006063:Chorionic Gonadotropin; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D019326:17-alpha-Hydroxyprogesterone; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone